Loading...
XNAS
MRSN
Market cap50mUSD
Jun 10, Last price  
0.41USD
1D
4.15%
1Q
-20.24%
IPO
-96.99%
Name

Mersana Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:MRSN chart
No data to show
P/E
—
P/S
1.25
EPS
—
Div Yield, %
—
Shrs. gr., 5y
23.02%
Rev. gr., 5y
-0.78%
Revenues
40m
+9.88%
10,359,00025,171,00017,545,00010,594,00042,123,000828,00043,00026,581,00036,855,00040,497,000
Net income
-69m
L-59.69%
-16,428,000-13,700,000-38,707,000-64,257,000-27,197,000-88,404,000-169,205,000-207,540,000-171,670,000-69,192,000
CFO
-82m
L-51.24%
-9,636,00031,588,000-42,679,000-55,216,000-67,744,000-74,696,000-139,988,000-49,363,000-168,882,000-82,340,000
Earnings
Aug 11, 2025

Profile

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
URL
https://www.mersana.com/
IPO date
Jun 28, 2017
Employees
228
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
40,497
9.88%
36,855
38.65%
26,581
61,716.28%
Cost of revenue
113,833
356,081
231,275
Unusual Expense (Income)
NOPBT
(73,336)
(319,226)
(204,694)
NOPBT Margin
Operating Taxes
418
3,328
Tax Rate
NOPAT
(73,754)
(319,226)
(208,022)
Net income
(69,192)
-59.69%
(171,670)
-17.28%
(207,540)
22.66%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,780
93,539
3,461
BB yield
-3.30%
-34.72%
-0.63%
Debt
Debt current
16,356
5,479
2,798
Long-term debt
6,440
36,752
44,877
Deferred revenue
97,167
117,043
Other long-term liabilities
90,422
1,000
203
Net debt
(111,824)
(166,853)
(233,515)
Cash flow
Cash from operating activities
(82,340)
(168,882)
(49,363)
CAPEX
(132)
(2,168)
(2,197)
Cash from investing activities
11,437
119,883
(152,716)
Cash from financing activities
4,092
94,675
153,017
FCF
(69,010)
(316,291)
(207,625)
Balance
Cash
134,620
209,084
280,712
Long term investments
478
Excess cash
132,595
207,241
279,861
Stockholders' equity
(895,531)
(826,338)
(654,832)
Invested Capital
994,092
994,240
900,437
ROIC
ROCE
EV
Common stock shares outstanding
122,540
116,113
93,654
Price
1.43
-38.36%
2.32
-60.41%
5.86
-5.79%
Market cap
175,232
-34.95%
269,382
-50.92%
548,814
25.01%
EV
63,408
102,529
315,299
EBITDA
(71,708)
(317,709)
(203,767)
EV/EBITDA
Interest
3,874
4,073
3,328
Interest/NOPBT